Pralsetinib for treating RET fusion-positive locally advanced or metastatic non-small-cell lung cancer

Published on 01 Sep 2023
Last Updated on 01 Sep 2023

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee is unable to make a recommendation on pralsetinib for inclusion on the MOH List of Subsidised Drugs because the company has withdrawn its application from the company-led submission process due to the decision to end its global collaboration agreement to develop and commercialise pralsetinib. This submission was for treating rearranged during transfection (RET) fusion-positive, locally advanced or metastatic non-small-cell lung cancer.

Pralsetinib for treating RET fusion-positive locally advanced or metastatic non-small-cell lung cancer (Published 1 Sep 23) [PDF, 97 KB]